Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Andrew D. Sklawer net worth and biography

Andrew Sklawer Biography and Net Worth

COO of Brickell Biotech

Andy Sklawer has 15 years of experience in building and operating development-stage companies.
Prior to co-founding Brickell, he served as the Head of Operations at Concordia Pharmaceuticals, Inc., an oncology drug development company acquired by Kadmon Corporation in 2011. Prior to Concordia, Mr. Sklawer held various positions with increasing responsibility at Verid, Inc., a developer of security technology prior to and subsequent to its acquisition by EMC Corporation.

Mr. Sklawer holds a B.S. degree in Marketing from the University of Florida and received his M.B.A. from the University of Miami. Andy currently serves as a Board Member for StartUp FIU and on the Advisory Committee of the Advancing Innovation in Dermatology Accelerator Fund.

What is Andrew D. Sklawer's net worth?: The estimated net worth of Andrew D. Sklawer is at least $0.00 as of May 17th, 2021. Mr. Sklawer owns 124,625 shares of Brickell Biotech stock worth more than $0 as of April 20th. This net worth evaluation does not reflect any other assets that Mr. Sklawer may own. Additionally, Mr. Sklawer receives an annual salary of $559,580.00 as COO at Brickell Biotech. Learn More about Andrew D. Sklawer's net worth.
How old is Andrew D. Sklawer?: Mr. Sklawer is currently 38 years old. There are 6 older executives and no younger executives at Brickell Biotech. The oldest executive at Brickell Biotech is Mr. Albert Nicholas Marchio II, CFO and Principal Accounting & Financial Officer, who is 70 years old. Learn More on Andrew D. Sklawer's age.
What is Andrew D. Sklawer's salary?: As the COO of Brickell Biotech, Inc., Mr. Sklawer earns $559,580.00 per year. The highest earning executive at Brickell Biotech is Attorney Robert Busard Brown, CEO & Director, who commands a salary of $816,730.00 per year. Learn More on Andrew D. Sklawer's salary.
How do I contact Andrew D. Sklawer?: The corporate mailing address for Mr. Sklawer and other Brickell Biotech executives is 5777 CENTRAL AVENUE SUITE 102, BOULDER CO, 80301. Brickell Biotech can also be reached via phone at (720) 505-4755 and via email at [email protected]. Learn More on Andrew D. Sklawer's contact information.
Has Andrew D. Sklawer been buying or selling shares of Brickell Biotech?: Andrew D. Sklawer has not been actively trading shares of Brickell Biotech in the last ninety days. Most recently, on Monday, May 17th, Andrew D. Sklawer bought 15,375 shares of Brickell Biotech stock. The stock was acquired at an average cost of $0.80 per share, with a total value of $12,300.00. Following the completion of the transaction, the chief operating officer now directly owns 124,625 shares of the company's stock, valued at $99,700. Learn More on Andrew D. Sklawer's trading history.
Who are Brickell Biotech's active insiders?: Brickell Biotech's insider roster includes Robert Brown (CEO), Deepak Chadha (Insider), Reginald Hardy (Chairman), David McAvoy (General Counsel), and Andrew Sklawer (COO). Learn More on Brickell Biotech's active insiders.

Andrew D. Sklawer Insider Trading History at Brickell Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/17/2021	Buy	15,375	$0.80	$12,300.00	124,625

Andrew D. Sklawer Buying and Selling Activity at Brickell Biotech

Brickell Biotech Company Overview

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Today's Range

Now: N/A

50 Day Range

MA: $0.86

$0.77

$0.93

2 Week Range

Now: N/A

Volume

31,300 shs

Average Volume

206,730 shs

Market Capitalization

$6.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.02

Secret Bull Market Starts in This Unusual Sector

From Altimetry | Ad